Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
NCT03734952

Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy

Led by Fujian Medical University Union Hospital · Updated on 2023-09-25

537

Participants Needed

1

Research Sites

296 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The primary objective is to compare surgery with postoperative radiotherapy (PORT) versus surgery, in terms of the overall survival time (OS) in Stage II or III squamous cell esophageal carcinoma with neoadjuvant chemoradiotherapy(nCRT).

CONDITIONS

Official Title

Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients must have histologically confirmed squamous cell carcinoma of the esophagus
  • Tumors located in the thoracic cavity
  • Pre-treatment stage II or III (AJCC/UICC 8th Edition)
  • Male or non-pregnant female
  • Age between 18 and 65 years
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1 or Karnofsky performance status (KPS) of 70 or higher
  • Adequate bone marrow function: White Blood Cells ≥4x10^9/L; Neutrophils ≥1.5x10^9/L; Hemoglobin ≥90 g/L; Platelets ≥100x10^9/L
  • Adequate liver function: Total bilirubin, AST and ALT ≤2 times upper limit of normal
  • Adequate renal function: Serum creatinine ≤1.5 times upper limit of normal
  • Provided written informed consent and able to understand and comply with the study
Not Eligible

You will not qualify if you...

  • Non-squamous cell carcinoma histology
  • Advanced inoperable or metastatic esophageal cancer
  • Another previous or current malignant disease
  • Significant medical conditions unlikely to tolerate therapies, such as cardiac disease
  • Age over 65 years
  • Pregnant or lactating females or those unwilling to use contraceptives
  • Uncontrolled seizures or psychiatric diseases with loss of behavioral control
  • Refusal of surgery after neoadjuvant chemotherapy
  • Considered unsuitable for trial enrollment by investigators

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Fujian Medical University Union Hospital

Fuzhou, Fujian, China, 350000

Actively Recruiting

Loading map...

Research Team

B

Benhua Xu, doctor

CONTACT

J

Jianyuan Song, doctor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here